Basic Information
| RNALocate ID: | RLID:11003981 |
| RNA Symbol: | hsa-miR-193b-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-193b* |
| RNA ID: | miRBase:MIMAT0004767 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23666971 |
| Tissue/Cell Line: | Follicular fluid |
| Method: | Microarray |
| Description: | The TaqMan miRNA Array Card version 3.0, which includes 766 mature miRNAs, detected the presence of miRNAs in both the microvesicles and the supernatant. A total of 120 miRNAs (cycle threshold [Ct] <37) were found in the in microvesicles extracted from 8 mL fresh follicular fluid, and 82 miRNAs (Ct <37) were expressed in 500 uL supernatant (Table 2). Data are collected from Table 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002661 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01002662 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002663 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11003978 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11003979 | Exosome | Plasma | 23663360 |
| RLID:11003980 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000684 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001551 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-193b-5p | Lymphoma | MNDR-E-MI-23217 |
| MNDR | hsa-miR-193b-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-23218 |
| MNDR | hsa-miR-193b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-23219 |
| MNDR | hsa-miR-193b-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-23220 |
| MNDR | hsa-miR-193b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-23221 |
| MNDR | hsa-miR-193b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-23222 |
| MNDR | hsa-miR-193b-5p | Breast cancer luminal | MNDR-E-MI-23223 |
| MNDR | hsa-miR-193b-5p | Prostate cancer | MNDR-E-MI-23224 |
| MNDR | hsa-miR-193b-5p | Gastric cancer | MNDR-E-MI-23225 |
| MNDR | hsa-miR-193b-5p | Alzheimer disease | MNDR-E-MI-23226 |
| MNDR | hsa-miR-193b-5p | Intracranial aneurysm | MNDR-E-MI-23227 |
| MNDR | hsa-miR-193b-5p | Leukemia | MNDR-E-MI-23228 |
| MNDR | hsa-miR-193b-5p | Huntington disease | MNDR-E-MI-23229 |
| MNDR | hsa-miR-193b-5p | Chorea | MNDR-E-MI-23230 |
| MNDR | hsa-miR-193b-5p | Lung cancer | MNDR-E-MI-23231 |
| MNDR | hsa-miR-193b-5p | Parkinson disease | MNDR-E-MI-23232 |
| MNDR | hsa-miR-193b-5p | Basal-like breast cancer | MNDR-E-MI-23233 |
| MNDR | hsa-miR-193b-5p | Thyroid cancer | MNDR-E-MI-23234 |
| MNDR | hsa-miR-193b-5p | Pancreatic cancer | MNDR-E-MI-23235 |
| MNDR | hsa-miR-193b-5p | Melanoma | MNDR-E-MI-23236 |
| MNDR | hsa-miR-193b-5p | Rectum adenocarcinoma | MNDR-E-MI-23237 |
| MNDR | hsa-miR-193b-5p | Nephroblastoma | MNDR-E-MI-23238 |
| MNDR | hsa-miR-193b-5p | Colon adenocarcinoma | MNDR-E-MI-23239 |
| MNDR | hsa-miR-193b-5p | Familial ovarian cancer | MNDR-E-MI-23240 |
| MNDR | hsa-miR-193b-5p | Carcinoma ductal breast | MNDR-E-MI-23241 |
| MNDR | hsa-miR-193b-5p | Liposarcoma | MNDR-E-MI-23242 |
| MNDR | hsa-miR-193b-5p | Liver cancer | MNDR-E-MI-23243 |
| MNDR | hsa-miR-193b-5p | Gastric adenocarcinoma | MNDR-E-MI-23244 |
| MNDR | hsa-miR-193b-5p | Lung squamous cell carcinoma | MNDR-E-MI-23245 |
| MNDR | hsa-miR-193b-5p | Lung adenocarcinoma | MNDR-E-MI-23246 |
| MNDR | hsa-miR-193b-5p | Thyroid carcinoma | MNDR-E-MI-23247 |
| MNDR | hsa-miR-193b-5p | Bladder urothelial carcinoma | MNDR-E-MI-23248 |
| MNDR | hsa-miR-193b-5p | Pancreatic adenocarcinoma | MNDR-E-MI-23249 |
| MNDR | hsa-miR-193b-5p | Carcinoma renal cell | MNDR-E-MI-23250 |
| MNDR | hsa-miR-193b-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-23251 |
| MNDR | hsa-miR-193b-5p | Renal clear cell carcinoma | MNDR-E-MI-23252 |
| MNDR | hsa-miR-193b-5p | Biliary tract cancer | MNDR-E-MI-23253 |
| MNDR | hsa-miR-193b-5p | Cholangiocarcinoma | MNDR-E-MI-23254 |
| MNDR | hsa-miR-193b-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-23255 |
| MNDR | hsa-miR-193b-5p | Testicular germ cell cancer | MNDR-E-MI-23256 |
| MNDR | hsa-miR-193b-5p | Breast invasive carcinoma | MNDR-E-MI-23257 |
| MNDR | hsa-miR-193b-5p | Hepatocellular carcinoma | MNDR-E-MI-23258 |
| MNDR | hsa-miR-193b-5p | Familiar ovarian carcinoma | MNDR-E-MI-23259 |
| MNDR | hsa-miR-193b-5p | B-cell lymphoma | MNDR-E-MI-23260 |
| MNDR | hsa-miR-193b-5p | Malignant pleural mesothelioma | MNDR-E-MI-23261 |
| MNDR | hsa-miR-193b-5p | Retinoblastoma | MNDR-E-MI-23262 |
| MNDR | hsa-miR-193b-5p | Barrett's adenocarcinoma | MNDR-E-MI-23263 |
| MNDR | hsa-miR-193b-5p | Hodgkin lymphoma | MNDR-E-MI-23264 |
| MNDR | hsa-miR-193b-5p | Psoriasis | MNDR-E-MI-23265 |
| MNDR | hsa-miR-193b-5p | Skin cutaneous melanoma | MNDR-E-MI-23266 |
| MNDR | hsa-miR-193b-5p | Skin melanoma | MNDR-E-MI-23267 |
| MNDR | hsa-miR-193b-5p | Colorectal cancer | MNDR-E-MI-23268 |
| MNDR | hsa-miR-193b-5p | Nasopharynx carcinoma | MNDR-E-MI-23269 |
| MNDR | hsa-miR-193b-5p | Multiple myeloma | MNDR-E-MI-23270 |
| MNDR | hsa-miR-193b-5p | Nasopharyngeal cancer | MNDR-E-MI-23271 |
| MNDR | hsa-miR-193b-5p | Barrett's carcinogenesis | MNDR-E-MI-23272 |
| MNDR | hsa-miR-193b-5p | Breast cancer her3+ negative | MNDR-E-MI-23273 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CRIM1 | Homo sapiens | RR00365338 |
TOP